Practical applications of intravesical chemotherapy and immunotherapy in high-risk patients with superficial bladder cancer. (Q36111213)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15862610%20AND%20SRC:MED&resulttype=core&format=json

11 January 2020

review article

1 reference

title

Practical applications of intravesical chemotherapy and immunotherapy in high-risk patients with superficial bladder cancer (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15862610%20AND%20SRC:MED&resulttype=core&format=json

11 January 2020

1 reference

1 reference

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15862610%20AND%20SRC:MED&resulttype=core&format=json

11 January 2020

author name string

Michael A O'Donnell

series ordinal

1

1 reference

12 August 2017

publication date

1 May 2005

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15862610%20AND%20SRC:MED&resulttype=core&format=json

Urologic Clinics of North America

11 January 2020

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15862610%20AND%20SRC:MED&resulttype=core&format=json

11 January 2020

volume

32

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15862610%20AND%20SRC:MED&resulttype=core&format=json

11 January 2020

issue

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15862610%20AND%20SRC:MED&resulttype=core&format=json

11 January 2020

page(s)

121-131

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15862610%20AND%20SRC:MED&resulttype=core&format=json

Primary superficial bladder cancer risk groups according to progression, mortality and recurrence.

11 January 2020

cites work

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2005.01.003

Up-front intravesical chemotherapy for low stage, low grade recurrent bladder cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2005.01.003

Residual tumor discovered in routine second transurethral resection in patients with stage T1 transitional cell carcinoma of the bladder

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2005.01.003

The value of a second transurethral resection in evaluating patients with bladder tumors

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2005.01.003

A single immediate postoperative instillation of chemotherapy decreases the risk of recurrence in patients with stage Ta T1 bladder cancer: a meta-analysis of published results of randomized clinical trials

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2005.01.003

The effect of intravesical thiotepa on tumour recurrence after endoscopic treatment of newly diagnosed superficial bladder cancer. A further report with long-term follow-up of a Medical Research Council randomized trial. Medical Research Council Wor

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2005.01.003

Factors explaining recurrence in patients undergoing chemoimmunotherapy regimens for frequently recurring superficial bladder carcinoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2005.01.003

Mitomycin C resorption following repeated intravesical instillations using different instillation times

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2005.01.003

Recurrence of superficial bladder carcinoma after intravesical instillation of mitomycin-C. Comparison of exposure times

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2005.01.003

A phase II study of prophylactic intravesical chemotherapy with 4'-epirubicin in recurrent superficial bladder cancer: comparison of 4'-epirubicin and adriamycin

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2005.01.003

Comparison of the prophylactic usefulness of epirubicin and doxorubicin in the treatment of superficial bladder cancer by intravesical instillation: a multicenter randomized trial. Kobe University Urological Oncology Group

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2005.01.003

Intravesical epirubicin versus doxorubicin for superficial bladder tumors (stages pTa and pT1): a randomized prospective study.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2005.01.003

Guidelines on bladder cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2005.01.003

Effect of prophylactic treatment with intravesical epirubicin on recurrence of superficial bladder cancer--The 6th Trial of the Japanese Urological Cancer Research Group (JUCRG): a randomized trial of intravesical epirubicin at dose of 20mg/40ml, 30

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2005.01.003

Pharmacokinetics of intravesical doxorubicin in superficial bladder cancer patients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2005.01.003

Methods to improve efficacy of intravesical mitomycin C: results of a randomized phase III trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2005.01.003

The effect of fasting or desmopressin before treatment on the concentration of mitomycin C during intravesical administration.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2005.01.003

Intravesical chemotherapy with epirubicin: a dose response study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2005.01.003

Long-term versus short-term doxorubicin hydrochloride instillation after transurethral resection of superficial bladder cancer.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2005.01.003

Natural history and treatment of low and high risk superficial bladder tumors

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2005.01.003

Comparison of different schedules of cytostatic intravesical instillations in patients with superficial bladder carcinoma: final evaluation of a prospective multicenter study with 419 patients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2005.01.003

A randomized controlled trial of short-term versus long-term prophylactic intravesical instillation chemotherapy for recurrence after transurethral resection of Ta/T1 transitional cell carcinoma of the bladder

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2005.01.003

Intravesical chemotherapy prophylaxis in primary superficial bladder cancer: a meta-analysis of 3703 patients from 11 randomized trials

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2005.01.003

Bladder carcinoma in situ in 2003: state of the art.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2005.01.003

Intravesical bacillus Calmette-Guérin is superior to mitomycin C in reducing tumour recurrence in high-risk superficial bladder cancer: a meta-analysis of randomized trials.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2005.01.003

Intravesical bacillus Calmette-Guerin versus mitomycin C for superficial bladder cancer: a formal meta-analysis of comparative studies on recurrence and toxicity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2005.01.003

Intravesical bacille Calmette-Guérin versus mitomycin C in superficial bladder cancer: formal meta-analysis of comparative studies on tumor progression.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2005.01.003

Intravesical bacillus Calmette-Guerin therapy for superficial bladder cancer: effect of bacillus Calmette-Guerin viability on treatment results

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2005.01.003

Five-year results of a phase II study with low-dose bacille Calmette-Guerin therapy in high-risk superficial bladder cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2005.01.003

Low Dose Pasteur Bacillus Calmette-Guerin Regimen in Stage T1, Grade 3 Bladder Cancer Therapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2005.01.003

Long-term follow-up of a randomized prospective trial comparing a standard 81 mg dose of intravesical bacille Calmette-Guérin with a reduced dose of 27 mg in superficial bladder cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2005.01.003

Dose-response of bacillus Calmette-Guerin in the treatment of superficial bladder cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2005.01.003

Single course versus maintenance bacillus Calmette-Guerin therapy for superficial bladder tumors: a prospective, randomized trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2005.01.003

A prospective randomized trial of maintenance versus nonmaintenance intravesical bacillus Calmette-Guérin therapy of superficial bladder cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2005.01.003

Tolerability of bacille Calmette-Guérin maintenance therapy for superficial bladder cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2005.01.003

Treatment of high-risk superficial bladder cancer with maintenance bacille Calmette-Guérin therapy: preliminary results

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2005.01.003

Maintenance Bacillus Calmette-Guerin for Ta T1 Bladder Tumors Is Not Associated with Increased Toxicity: Results from a European Organisation for Research and Treatment of Cancer Genito-Urinary Group Phase III Trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2005.01.003

Modified induction course: a solution to side-effects?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2005.01.003

Long-term results of intravesical bacillus Calmette-Guérin therapy for stage T1 superficial bladder cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2005.01.003

Intravesical bacillus Calmette-Guerin in the treatment of superficial transitional cell carcinoma of the bladder

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2005.01.003

Superficial bladder cancer: progression and recurrence

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2005.01.003

Prognostic parameters in superficial bladder cancer: an analysis of 315 cases

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2005.01.003

Risks and benefits of repeated courses of intravesical bacillus Calmette-Guerin therapy for superficial bladder cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2005.01.003

Superficial bladder cancer: the role of interferon-alpha.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2005.01.003

Alpha-interferon in superficial bladder cancer: a Northern California Oncology Group Study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2005.01.003

Efficacy of escalating doses of intravesical interferon alpha-2b in reducing recurrence rate and progression in superficial transitional cell carcinoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2005.01.003

A randomized comparative dose-ranging study of interferon-alpha and mitomycin-C as an internal control in primary or recurrent superficial transitional cell carcinoma of the bladder

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2005.01.003

Results at 43 months' follow-up of a double-blind, randomized, prospective clinical trial using intravesical interferon alpha-2b in the prophylaxis of stage pT1 transitional cell carcinoma of the bladder

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2005.01.003

Intravesical immunoprophylaxis in recurrent superficial bladder cancer (Stage T1): multicenter trial comparing bacille Calmette-Guérin and interferon-alpha

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2005.01.003

Bacillus Calmete-Guérin plus interferon-alpha2B intravesical therapy maintains an extended treatment plan for superficial bladder cancer with minimal toxicity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2005.01.003

Salvage intravesical therapy with interferon-alpha 2b plus low dose bacillus Calmette-Guerin is effective in patients with superficial bladder cancer in whom bacillus Calmette-Guerin alone previously failed

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2005.01.003

Interim results from a national multicenter phase II trial of combination bacillus Calmette-Guerin plus interferon alfa-2b for superficial bladder cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2005.01.003

Efficacy and safety of valrubicin for the treatment of Bacillus Calmette-Guerin refractory carcinoma in situ of the bladder. The Valrubicin Study Group

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2005.01.003

New drugs and new approaches for the treatment of metastatic urothelial cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2005.01.003

Efficacy of paclitaxel released from bio-adhesive polymer microspheres on model superficial bladder cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2005.01.003

Intravesical gemcitabine therapy for superficial transitional cell carcinoma of the bladder: a phase I and pharmacokinetic study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2005.01.003

Phase I trial of intravesical gemcitabine in bacillus Calmette-Guérin-refractory transitional-cell carcinoma of the bladder.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2005.01.003

Intravesical administration of gemcitabine in superficial bladder cancer: a phase I study with pharmacodynamic evaluation.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2005.01.003

Phase II study to investigate the ablative efficacy of intravesical administration of gemcitabine in intermediate-risk superficial bladder cancer (SBC).

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2005.01.003

Multicentric Study Comparing Intravesical Chemotherapy Alone and With Local Microwave Hyperthermia for Prophylaxis of Recurrence of Superficial Transitional Cell Carcinoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2005.01.003

Combined local bladder hyperthermia and intravesical chemotherapy for the treatment of high-grade superficial bladder cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2005.01.003

Preliminary European Results of Local Microwave Hyperthermia and Chemotherapy Treatment in Intermediate or High Risk Superficial Transitional Cell Carcinoma of the Bladder

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2005.01.003

Intravesical electromotive mitomycin C versus passive transport mitomycin C for high risk superficial bladder cancer: a prospective randomized study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2005.01.003

Photodynamic therapy with intravesical instillation of 5-aminolevulinic acid for patients with recurrent superficial bladder cancer: a single-center study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2005.01.003

Hypericin as a potential phototherapeutic agent in superficial transitional cell carcinoma of the bladder

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2005.01.003

10.1016/J.UCL.2005.01.003

7 January 2021

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15862610%20AND%20SRC:MED&resulttype=core&format=json

11 January 2020

1 reference